- Sarah Millard, Medically reviewed by Luke Wright, PharmD
- 6 days ago
- 5 min read
Updated: 3 days ago
'
Peptide therapy and the rise of personalized medicine
Amino acids are kind of like Legos. Connect them together and you've got a stack. That stack - or chain - is a peptide. Each chain has its own unique sequence, shape, and functional profile. For the uninitiated: peptides are signaling molecules that bind to specific cell-surface receptors, triggering a conformational change that begins a cascade of reactions that alter how the cell functions at the molecular level.
Rather than fitting neatly into one signaling category, peptides can be found in nearly every major intercellular communication system in the body. They can function as peptide hormones, neurotransmitters, growth factors, ion channel ligands, and cytokines - sometimes simultaneously. This is precisely what makes them unusual as a drug class - peptides don't have a lane.
Peptides - and why clinicians are paying attention
There is a clinical momentum behind peptide therapeutics, and it's not a trend. Decades of foundational science support a therapeutic class that now spans metabolic health, inflammation, hormone signaling, and regenerative medicine.
Why peptides
Small molecule therapeutics can lack selectivity - they are so small that they can slide into multiple binding sites and interact with unintended receptors, enzymes, and proteins. The drug hits the intended target and works, but it also does things elsewhere that it doesn't need to do. Simultaneously, large biologics have a greater chance of being recognized and attacked by the immune system due to their size and complexity, creating side effects and delivery challenges.
What distinguishes peptides from other therapeutics in this context is their precision. Peptides are strong candidates for use in clinical settings because they are highly selective - hitting their intended target and communicating with cell receptors that were built to receive them. Their specificity is what makes peptides well-suited for personalized medicine.
Peptides are not experimental fringe medicine. They are a therapeutic class with over a century of clinical use, and the debates now unfolding around compounding access are the latest chapter in a long, ongoing negotiation between pharmaceutical innovation, patient access, and regulatory oversight.
The unfolding regulatory landscape
The current regulatory discussion
The Pharmacy Compounding Advisory Committee (PCAC) is an advisory body established by the FDA to evaluate bulk drug substances nominated for the 503A Bulks List - the list that governs what compounding pharmacies can legally prepare. PCAC panels bring together pharmacists, physicians, and scientists to assess clinical, pharmacological, and safety evidence for nominated substances. Their recommendations are non-binding, but the FDA has historically followed them closely.
The PCAC is scheduled to convene July 2026 to discuss seven peptides being considered for inclusion on the 503A Bulks List - including BPC-157, MOTs-C, Semax, and TB-500 - with another panel taking up five more peptides by February 2027.
The regulatory framework
The regulatory framework governing peptide compounding eligibility operates on a three-tier category system established under the Drug Quality and Security Act of 2013:
Compounding permitted
Substances with sufficient supporting safety information, such as semaglutide, PT-141, and Sermorelin, may be compounded under a valid patient-specific prescription while formal FDA evaluation continues.
Compounding prohibited
Substances flagged for safety risks or quality concerns cannot be compounded, effectively eliminating the only legal pathway for patients to obtain them through regulated channels. BPC-157, TB-500, and GHK-Cu were held here until the FDA's April 2026 decision.
Insufficient
data
The distinction from Category 2 matters: without enough supporting data to conduct a meaningful review, the FDA cannot permit compounding, regardless of clinical promise. Documentation is the holdup here, not safety concern.
On April 15, 2026, the FDA announced it would remove 12 peptide drug substances from Category 2, lifting the designation that had formed the basis for enforcement action against compounders distributing these peptides. Removal from Category 2 initiates the process - PCAC review and final FDA determination must still occur. The July 2026 PCAC meetings are the next procedural step, not the finish line. Formal rulemaking, which follows any positive committee recommendation, can take a year or more.
What's available now
Within the current compounding framework, clinicians have access to a meaningful and clinically relevant range of peptide formulations across therapeutic categories. Semaglutide and tirzepatide remain available through 503A compounding when a prescriber can determine and document a clinical difference that commercially available products cannot provide. Sermorelin, a GHRH analog, is available in sublingual drops and troches, while PT-141 (bremelanotide) is available in compounded sublingual drops and nasal spray formats. GHK-Cu - now removed from Category 2 and headed for PCAC review February 2027 - is a formulation worth monitoring. The broader pipeline of peptides now moving through the PCAC process represents potential future additions to the compounding landscape.
The case for clinical partnership
Formulation decisions carry clinical weight, regulatory requirements are specific and evolving, and patient populations often have needs that standard commercial options cannot meet. The relationship between prescribing clinician and compounding pharmacist is infrastructural, and the collaboration can have measurable downstream effects on patient outcomes.
The role of the compounding pharmacist
When a clinical case calls for a compounded formulation, the pharmacist's role extends beyond the preparation. A skilled compounding pharmacist can advise on formulation selection and absorption profile, identify whether a documentable clinical difference exists, provide documentation support that protects the patient and prescribing clinicians in a regulatory environment, and serve as a standing resource during treatment.
For Esatto, this role is central to how the pharmacy operates. Pharmacist-led compounding, small-batch precision, and ongoing provider collaboration are not marketing language - they are an operating model. For practices managing complex patients, a pharmacist partner who understands the peptide landscape can help reduce the time and burden your team spends navigating regulatory and formulation challenges case by case.
What to look for in a compounding partner
As clinical standards for compounding peptides become more explicit, the criteria for evaluating a compounding partner becomes more consequential. Here is what matters:
Quality sourcing. Active pharmaceutical ingredients should be sourced from FDA-registered cGMP-compliant suppliers. The molecular integrity of the starting material impacts what happens downstream, and sourcing from unvetted suppliers that lack oversight can create product variability that generates adverse effects and draws FDA scrutiny.
Testing standards. USP <797>, updated November 2023, governs sterile preparations - including injectable peptides - and requires sterility testing, bacterial endotoxin testing, and potency verification of the finished preparation. Non-sterile formulations - sublingual drops, troches, and topical creams - fall under USP <795>, which establishes quality, identity, and potency standards. Both chapters are incorporated into regulations by most state boards of pharmacy and represent the standard of care for compounded peptide products.
Formulation expertise. Peptides can be sensitive to pH, temperature, light exposure, oxidation, and degradation, with formulation decisions directly affecting the final prepared product. A pharmacy with expertise in peptide formulation helps to ensure preparations perform as intended.
Provider support. The right pharmacy partner functions as a clinical resource. This means accessible pharmacist consultation, formulation guidance for case-specific needs, documentation support, and proactive communication as regulations evolve. This kind of support infrastructure translates into case throughput - fewer holdups and more time focused on patients rather than paperwork.
The future of peptides
The regulatory landscape will keep moving, and the PCAC meetings scheduled for July 2026 and early 2027 will bring clarity to the status of compounds that have been in a regulatory limbo for years, with the outcomes shaping what compounding pharmacies can offer, and what providers can prescribe, for the foreseeable future. Practices that stay informed and stay connected to compliance-forward pharmacy partners will be positioned to integrate new peptide therapy options swiftly and responsibly as the picture develops.
For providers, a compounding pharmacy that sources with integrity and maintains a genuine clinical partnership with the practices it serves is not just a vendor. It is a meaningful extension of the care you provide, and it is how personalized medicine gets delivered. One patient, one prescription, one carefully compounded formulation at a time.
Our provider portal is the place to start. Existing formulations are available now, and as the regulatory picture develops, we'll be the first to let you know what's next.